Cassian Yee, M.D.

The University of Texas MD Anderson Cancer Center
Houston, TX

Dr. Cassian Yee is the director of Solid Tumor Cell Therapy in the Center for Cancer Immunology Research and a professor in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center.

Dr. Yee is a pioneer in adoptive cell transfer (ACT) immunotherapy, which involves taking anti-cancer T cells from patients and then enhancing their anti-tumor capabilities before putting them back into patients. In this area, he helped establish standards for the process, demonstrated that these T cells can confer durable anti-tumor memory, and showed how checkpoint immunotherapy can enhance ACT’s effects. In addition to being a member of CRI’s Scientific Advisory Council, Dr. Yee is a leader of the CRI-SU2C Dream Team, serves on the Postdoctoral Fellowship Review Committee, and is a member of CRI’s global clinical investigator network.

Combining CTLA4 blockade with the transfer of well-characterized, robust antitumor T cells represents an encouraging strategy to enhance the activity of the adoptively transferred T cells and induce antitumor responses.
Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.